Discounted Cash Flow (DCF) Analysis Levered

Enzo Biochem, Inc. (ENZ)

$1.2697

+0.02 (+1.58%)
All numbers are in Millions, Currency in USD
Stock DCF: -1.22 | 1.2697 | overvalue

Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue 81.1776.02117.73107.0731.0628.6126.3624.2822.3720.61
Revenue (%)
Operating Cash Flow 4.81-17.180.39-16.59-36.98-8.63-7.95-7.33-6.75-6.22
Operating Cash Flow (%)
Capital Expenditure -8.13-2.17-4.44-3.47-2.76-1.65-1.52-1.40-1.29-1.19
Capital Expenditure (%)
Free Cash Flow -3.32-19.35-4.05-20.06-39.74-10.28-9.47-8.72-8.04-7.40

Weighted Average Cost Of Capital

Share price $ 1.2,697
Beta 0.907
Diluted Shares Outstanding 49.16
Cost of Debt
Tax Rate 181.08
After-tax Cost of Debt -4.05%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.603
Total Debt 7
Total Equity 62.42
Total Capital 69.42
Debt Weighting 10.08
Equity Weighting 89.92
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue 81.1776.02117.73107.0731.0628.6126.3624.2822.3720.61
Operating Cash Flow 4.81-17.180.39-16.59-36.98-8.63-7.95-7.33-6.75-6.22
Capital Expenditure -8.13-2.17-4.44-3.47-2.76-1.65-1.52-1.40-1.29-1.19
Free Cash Flow -3.32-19.35-4.05-20.06-39.74-10.28-9.47-8.72-8.04-7.40
WACC
PV LFCF -9.58-8.22-7.06-6.06-5.20
SUM PV LFCF -36.11

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.33
Free cash flow (t + 1) -7.55
Terminal Value -141.68
Present Value of Terminal Value -99.47

Intrinsic Value

Enterprise Value -135.58
Net Debt -75.38
Equity Value -60.20
Shares Outstanding 49.16
Equity Value Per Share -1.22